Database for high-risk nasopharyngeal carcinoma treated with chemoradiotherapy and immunotherapy

This dataset originates from a multicenter, open-label, randomized
controlled trial investigating the efficacy of adding anti-PD-1
immunotherapy to concurrent chemoradiotherapy and adjuvant therapy
following induction chemotherapy in patients with high-risk nasopharyngeal
carcinoma (NPC). The primary research hypothesis is that the
intensification of therapy with PD-1 inhibitors during and after
concurrent chemoradiotherapy will significantly reduce the disease
progression rate and improve overall survival outcomes for this high-risk
patient population. Data includes comprehensive baseline patient
characteristics, treatment details, and follow-up data for survival and
disease status endpoints. This data set possesses significant reuse
potential. Researchers can perform analyses to validate the primary
findings, explore subgroup effects, or generate new hypotheses. Also, it
can serve as a benchmark for developing or validating novel statistical
methods or prognostic models for survival data analysis. And the dataset
can be used for meta-analyses, providing the highest level of evidence to
refine the treatment guidelines for high-risk nasopharyngeal carcinoma.
The study protocol was approved by the ethics committee of each
participating center. The trial was performed in accordance with the
Declaration of Helsinki, and the results were reported according to the
CONSORT statement.